iCAD and Cascaid Health Partner to Revolutionize Breast Cancer Detection with AI-Powered Solutions

iCAD Unveils Next-Generation AI Solutions for Breast Cancer Detection

iCAD, Inc. (NASDAQ: ICAD), a leader in AI-powered cancer detection solutions, is set to showcase its latest breast health AI technologies at the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago from December 1-5 1

1

2

2

. The company's presentation will highlight two significant developments: the recently FDA-cleared ProFound Detection Version 4 and a new partnership with Cascaid Health.

ProFound Detection Version 4: Advancing Breast Cancer Screening

ProFound Detection Version 4, iCAD's flagship AI solution, has received FDA clearance and represents a significant leap in breast cancer detection technology. This next-generation AI system enhances cancer detection by incorporating prior exams into current analysis, resulting in:

• 22% improvement in detecting aggressive cancers
• 18% reduction in cases with no marks
• More reliable insights for clinician decision-making 1

  1

  2

  2

Dana Brown, President and CEO of iCAD, emphasized the critical nature of early detection, stating, "Every two minutes, someone loses their life to breast cancer—a disease affecting over 2 million women annually. Early detection is critical, as five-year survival rates exceed 99% for stage 1 disease" 1

1

2

2

.

Partnership with Cascaid Health: Expanding AI Access

In a move to democratize access to AI-powered breast health services, iCAD has partnered with Cascaid Health. This collaboration will integrate the ProFound AI Breast Health Suite into Cascaid's digital health marketplace and access to care platform 1

1

2

2

. Key features of this partnership include:

1. ProFound Health: A virtual care model powered by Cascaid, scheduled for beta launch in Q1 2025
2. "Second Read" virtual AI service for patients without access to AI-read mammograms
3. Services including second-read detection, breast density assessment, and cancer risk evaluation
4. Access to a network of clinical experts in women's health through Cascaid's integrated digital platform 1

   1

   2

   2

Dr. Candace Westgate, Director of Women's Health for Cascaid Health, described ProFound Health as "more than just a technological innovation, it's a lifeline that empowers patients and healthcare providers with actionable insights" 1

1

2

2

.

Real-World Impact of AI in Breast Cancer Screening

Dr. Kathy Schilling, Medical Director of the Christine E. Lynn Women's Health & Wellness Institute at Boca Raton Regional Hospital, will present findings on the real-world effects of AI in breast cancer screening at RSNA 2024. Her team's experience with ProFound AI has shown significant improvements:

• 23% overall increase in cancer detection rates
• 4% rise in invasive cancer detection
• Doubled rates of lobular cancer detection
• 32% enhanced detection in dense breast tissue
• 12% reduction in invasive cancer size
• 40% reduction in T2 tumors 1

  1

These advancements demonstrate the transformative potential of AI in improving early breast cancer detection and patient outcomes.

Future Implications

The integration of AI technologies like ProFound Detection Version 4 and the partnership between iCAD and Cascaid Health represent a significant step forward in the fight against breast cancer. By improving detection rates, especially in challenging cases involving dense breast tissue, and expanding access to AI-powered screening, these innovations have the potential to save lives through earlier diagnosis and more personalized care.